NL-OMON39044已完成3 期
An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXT
nited Therapeutics Corporation0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Subjects who remained on study drug and completed all assessments during the Treatment Phase of Study TDE-PH-301 or TDE-PH-302 or TDE-PH-308 are eligible for this study.
- •2. Subjects who permanently discontinued study drug during the Treatment Phase of the previous study (TDE-PH-301 or TDE-PH-302 or TDE-PH-308) due to clinical worsening, who completed all visits and received placebo.
排除标准
- •1. Subjects who permanently discontinued study drug during the previous study (TDE-PH-301 or TDE-PH-302 or TDE-PH-308) due to treatment related adverse events
- •2. Subjects who permanently discontinued study drug during the Treatment Phase of the previous study (TDE-PH-301 or TDE-PH-302 or TDE-PH-308) due to clinical worsening, who completed all visits and received active medication.
- •3. Subjects who permanently discontinued study drug during the Treatment Phase of the previous study (TDE-PH-301 or TDE-PH-302 or TDE-PH-308) due to clinical worsening and who did not undergo all visits.
研究者
相似试验
进行中（未招募）
1 期
An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXTIdiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with :1) Appetite suppressant use or 2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years) or 3) Collagen Vascular Disease (CVD) or 4) Human Immunodeficiency Virus (HIV)MedDRA version: 8.1Level: PTClassification code 10037400Term: Pulmonary hypertensionEUCTR2006-000804-18-PTnited Therapeutics Corporation894
进行中（未招募）
1 期
An extension studyof UT-15C tablet in subjects with high blood pressure in the artery that carries blood to the lungsIdiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with :1) Appetite suppressant use or 2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years) or 3) Collagen Vascular Disease (CVD) or 4) Human Immunodeficiency Virus (HIV)MedDRA version: 16.0Level: PTClassification code 10037400Term: Pulmonary hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2006-000804-18-NLnited Therapeutics Corporation900
进行中（未招募）
1 期
An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXTIdiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with :1) Appetite suppressant use or 2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years) or 3) Collagen Vascular Disease (CVD) or 4) Human Immunodeficiency Virus (HIV)MedDRA version: 8.1Level: PTClassification code 10037400Term: Pulmonary hypertensionEUCTR2006-000804-18-FRnited Therapeutics Corporation450
进行中（未招募）
1 期
An extension study of UT-15C tablet in subjects with high blood pressure inthe artery that carries blood to the lungsIdiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with:1) Appetite suppressant/toxin use) or2) Repaired congenital systemic-to-pulmonary shunts (repaired = 5 years) or3) Collagen Vascular Disease (CVD)4) Human Immunosufficiency Virus (HIV)MedDRA version: 20.0Level: PTClassification code 10037400Term: Pulmonary hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2006-000804-18-ATnited Therapeutics Corporation900
进行中（未招募）
1 期
An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension - FREEDOM-EXTPulmonary Arterial Hypertension PAHMedDRA version: 9.1Level: LLTClassification code 10037400Term: Pulmonary hypertensionEUCTR2006-000804-18-ITITED THERAPEUTICS450